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Adrian Thrasher, a personal reflection from London: 
 
While happily training as a respiratory doctor in London, an eminent physician at the Royal 
Brompton Hospital came back from a meeting in the US and reported on an idea to treat 
cystic fibrosis using adenoviruses. The thing that puzzled him most was the fact that our 
immune system would surely eliminate the therapy. Even so I found the concept intriguing, 
and it stuck in the back of my mind for some time. Later, and further on in my clinical 
training, I was somewhat reluctantly hauled into the lab by Professor Tony Segal FRS to 
work on an enzyme system in phagocytes responsible for efficient microbial killing. It had 
been worked out that defects in this complex caused a severe inherited immunodeficiency 
called Chronic Granulomatous Disease. The realisation that basic scientific enquiry could 
lead to elucidation of disease mechanisms, and therefore to the design of novel therapies 
set me on a completely new path as an academic clinician. During my PhD I showed for the 
first time in 1992 that the NADPH-oxidase could be corrected in vitro by retrovirus-
mediated gene transfer, and at that point I entered a relatively nascent international gene 
therapy community. Soon after, I joined a pioneering bone marrow transplanter, Professor 
Roland Levinsky at the Institute of Child Health who had a vision that gene therapy would 
one day become a standard of care for many diseases. Early on he sent me on a trip to Palo 
Alto where a biotech company was beginning to explore the use of AAV for gene transfer. 
While I struggled to show anything meaningful in haematopoietic cells, it sparked a 
wonderful collaboration with Professor Robin Ali (current President ESGCT) culminating in 
one of the first clinical trials of gene therapy for an inherited blinding disorder, Leibers 
congenital amaurosis. When I started at The Institute of Child Health, I was fortunate to 
team up with Roland’s clinical fellow and PhD student Professor Bobby Gaspar who became 
a long-term colleague and friend. From scratch, we built a centre for gene therapy of 
inherited immunodeficiencies, recruiting our first patient with X-linked SCID in 2001, and 
since have treated more than 60 with a number of different diseases. Of course, over the 
last 30 years the field has faced difficulties, but alongside remarkable clinical progress and 
success, and today we are entering an era where gene therapy is becoming part of 
mainstream medicine. At Great Ormond Street Hospital for Children, we are now trialling 
gene addition and recently editing for inherited immunodeficiency, metabolic, and 
neuromuscular conditions, and increasingly for haematological malignancy. Perhaps most 
satisfying for me is that we are finally beginning to see real clinical benefit for patients with 
CGD, the disease that I worked on at the beginning of my career. I have been privileged 
along the way to work and collaborate with some exceptional scientists and clinicians many 
of whom have become good friends. I was particularly proud to receive the ESGCT 
outstanding achievement award in my home-town of Brighton in 2011, and continue to 
enjoy working with the board and on the educational initiatives established for training of 
young scientists. Most of all I have total respect for the families and patients who have 
participated in the development of these pioneering therapies, as without their courage and 
belief we would not be where we are today.  
